European generics firms, squeezed between innovators and payers, seek diversity
This article was originally published in SRA
Executive Summary
Mixed sentiments about the future of the European generic medicines sector were in evidence at the annual meeting of the European Generic medicines Association in Lisbon on 16-17 June1. Upbeat forecasts from industry figures contrasted with a more downbeat assessment from some consultancy firms in the face of the innovation slowdown, competition from R&D firms and the challenges posed by the biosimilars market.